pertuzumab: Clinical Trials

190 trials of pertuzumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

62 completed, 48 recruiting, 28 active not recruiting, 19 not yet recruiting. 190 Phase 2, 28 Phase 1, 8 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2190Completed 62, Recruiting 48, Active not recruiting 28, Not yet recruiting 19, Terminated 15, Unknown 15, Withdrawn 3
Phase 128Completed 8, Recruiting 8, Active not recruiting 6, Terminated 4, Unknown 1, Withdrawn 1
Phase 38Recruiting 4, Active not recruiting 2, Completed 1, Not yet recruiting 1

Follow pertuzumab: new trials by email Literature Review of pertuzumab trials Research Report on pertuzumab

Trials (filtered) newest first · largest first

All 190 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer
Retifanlimab, Trastuzumab (Herceptin), Pertuzumab - HER2-addicted Breast Cancer
Phase 2Not yet recruitingPolly A. Niravath, MD302026-12-312026-08-19
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
Alpelisib, Fulvestrant, Trastuzumab - PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)
Phase 2Not yet recruitingNovartis Pharmaceuticals512026-12-152026-09-18
HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers
HLX22, Serplulimab, trastuzumab - Gastric Cancer (Diagnosis), Colorectal Cancer (Diagnosis)
Phase 2Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology1282026-12-012026-11-16
SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response
SHR-A1811, Trastuzumab, Pertuzumab - HER2-positive Breast Cancer, Early Breast Cancer (EBC)
Phase 2Not yet recruitingFudan University3582026-10-012026-10-02
Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer
Fulvestaciclib, Trastuzumab, Pertuzumab - Breast Cancer, HER2-positive Breast Cancer
Phase 2Not yet recruitingFudan University2402026-10-012026-07-21
Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer
Trastuzumab (or biosimilar), Pertuzumab, Culmerciclib - Breast Cancer
Phase 2Not yet recruitingHebei Medical University Fourth Hospital312026-09-012026-10-19
Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer
Culmerciclib, Letrozole, Trastuzumab (TQB211) - Breast Cancer, HR Positive, HER2 Positive Breast Cancer
Phase 2Not yet recruitingShengjing Hospital332026-09-012026-08-31
Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
Paclitaxel oral solution plus Trastuzumab and Pertuzumab - HER2 + Breast Cancer
Phase 1 / Phase 2RecruitingLiu Shu302026-07-292026-08-04
Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer
Paclitaxel polymer micelles combined with trastuzumab, pertuzumab, and adrelumab, Taxanes combined with trastuzumab and pertuzumab. - Advanced HER2-positive Breast Cancer
Phase 2RecruitingFudan University1402026-07-282026-11-02
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
Dalpiciclib, Trastuzumab (Herceptin), Pertuzumab - Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast Cancer
Phase 2RecruitingSun Yat-sen University572026-06-012026-05-28
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
JSKN003, Trastuzumab, Pertuzumab - HER2-positive Recurrent or Metastatic Breast Cancer
Phase 2Not yet recruitingShanghai JMT-Bio Inc.602026-05-302026-04-22
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer
Fovinaciclib, Aromatase Inhibitors, Trastuzumab + Pertuzumab - HR+/HER2+ Early Breast Cancer
Phase 2RecruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine1002026-05-202026-06-01
Elacestrant in Advanced Triple Positive Breast Cancer
Elacestrant, Trastuzumab, Pertuzumab - ER Positive, HER2 Positive Breast Cancer
Phase 1 / Phase 2RecruitingNYU Langone Health502026-05-132026-05-28
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Trastuzumab (Herceptin), Pertuzumab, Combination product: Trastuzumab + Pertuzumab - Breast Cancer
Phase 2Not yet recruitingPeking University Cancer Hospital & Institute1562026-05-012026-04-17
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
SHR-A1811, Pertuzumab, trastuzumab - Breast Cancer
Phase 2Not yet recruitingHebei Medical University Fourth Hospital1002026-05-012026-04-14
Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)
Lipo-Dox®, Cyclophosphamide, Trastuzumab (Herceptin) - HER-2 Positive Breast Cancer
Phase 2Not yet recruitingNational Taiwan University Hospital542026-04-302026-05-04
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
Trastuzumab, Pertuzumab, Docetaxel - HER2-positive Early-stage Breast Cancer
Phase 2RecruitingRutgers, The State University of New Jersey502026-03-262026-04-23
Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer
THP Regimen (Taxane + Trastuzumab + Pertuzumab), Trastuzumab Rezetecan (SHR-A1811) - HER2-positive Breast Cancer
Phase 2RecruitingThe First Affiliated Hospital of Soochow University1242026-03-242026-06-15
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
Personalis NeXT Personal, Natera Signatera, fam-trastuzumab deruxtecan-nxki (T-DXd) - Breast Cancer, HER2-positive Breast Cancer
Phase 2RecruitingMemorial Sloan Kettering Cancer Center602026-03-042026-08-20
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
HLX87 + HLX22, HLX87 + Pertuzumab, T-Dxd + Pertuzumab - HER2 + Breast Cancer
Phase 2 / Phase 3RecruitingShanghai Henlius Biotech7062026-02-272026-03-20

Showing 20 of 190. Sign in to see all of them.

Conditions studied

Breast Neoplasms (115)  ·  Neoplasms (9)  ·  Neoplasm Metastasis (6)  ·  Stomach Neoplasms (6)  ·  Carcinoma, Non-Small-Cell Lung (5)  ·  Colorectal Neoplasms (5)  ·  Ovarian Neoplasms (5)  ·  Prostatic Neoplasms (5)  ·  Biliary Tract Neoplasms (4)  ·  Brain Neoplasms (4)  ·  Triple Negative Breast Neoplasms (4)  ·  Colonic Neoplasms (3)  ·  Hematologic Neoplasms (3)  ·  Inflammatory Breast Neoplasms (3)  ·  Lung Neoplasms (3)

Sponsors

Hoffmann-La Roche (17)  ·  Genentech, Inc. (12)  ·  Dana-Farber Cancer Institute (5)  ·  Fudan University (5)  ·  H. Lee Moffitt Cancer Center and Research Institute (5)  ·  Memorial Sloan Kettering Cancer Center (4)  ·  National Cancer Institute (NCI) (4)  ·  Shanghai Jiao Tong University School of Medicine (4)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (3)  ·  Shengjing Hospital (3)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2)  ·  Cancer Research UK (2)  ·  City of Hope Medical Center (2)  ·  European Organisation for Research and Treatment of Cancer - EORTC (2)  ·  German Cancer Research Center (2)

Countries

United States (86)  ·  China (39)  ·  Italy (27)  ·  Spain (26)  ·  France (24)  ·  Germany (24)  ·  United Kingdom (20)  ·  South Korea (12)  ·  Belgium (11)  ·  Brazil (11)  ·  Canada (11)  ·  Netherlands (11)  ·  Australia (10)  ·  Portugal (9)  ·  Poland (8)

Top investigators

Adrienne Waks, MD (2)  ·  Chau Dang, MD (2)  ·  Jordan Waypa, FNP (2)  ·  Matthew Krebs, Dr (2)  ·  Nancy Lin, MD (2)  ·  Aarti Bhardwaj, MD (1)  ·  Ajay Dhakal, MBBS (1)  ·  Alexios Matikas, MD/PhD (1)  ·  Amy Tiersten, MD (1)  ·  Andrea Botticelli (1)  ·  Andrea Pirzkall, M.D. (1)  ·  Andreas Schneeweiss, Prof. Dr. (1)  ·  Anna Dorothea Wagner, MD (1)

Results publications

PMID 28057664, PMID 20124182, PMID 21796368, PMID 22153890, PMID 22198468, PMID 22623692, PMID 22649152, PMID 23704196, PMID 24457379, PMID 24733796, PMID 25005255, PMID 26586415, PMID 26979312, PMID 27052654, PMID 27108243, PMID 27179402, PMID 27406346, PMID 27406347, PMID 27486629, PMID 27955684, PMID 28183321, PMID 28314836, PMID 28851423, PMID 29223479, PMID 29253081, PMID 29320312, PMID 29326029, PMID 29433963, PMID 30106636, PMID 30721110, PMID 30778520, PMID 30852761, PMID 30857956, PMID 31126258, PMID 31477168, PMID 31774522, PMID 31809243, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32463741, PMID 32701140, PMID 32988996, PMID 33048619, PMID 33068284, PMID 33090333, PMID 33242536, PMID 33736679, PMID 33844595, PMID 33945296

NIH funding

2018 (4), 2023 (4), 2014 (3), U10CA180820 (3), 2009 (2), 2017 (2), 2019 (2), 2025 (2), 2005 (1), 2016 (1), P30CA015083 (1), P30CA015704 (1), P30CA016672 (1), P30CA043703 (1), R01CA166020 (1)